Nielsen Leif Kofoed, Norderhaug Lars, Sandlie Inger, Dziegiel Morten Hanefeld
H:S Blodbank KI2033, Department of Clinical Immunology, Copenhagen University Hospital Copenhagen, Denmark.
APMIS. 2006 May;114(5):345-51. doi: 10.1111/j.1600-0463.2006.apm_381.x.
For over 35 years hemolytic disease of the fetus and newborn (HDFN) due to RhD has been effectively prevented by anti-RhD antibodies obtained from alloimmunized women or deliberately immunized men. However, due to the reduced number of immunized women and for ethical reasons it is foreseen that other sources of anti-RhD will be needed. One such source is recombinant human antibodies. Here we describe the construction of plasmids encoding two subclasses (IgG1 and IgG3) of an anti-RhD antibody, their transient expression in COS cells, and subsequent functional characterization of the antibodies with regard to specificity and ability to mediate a respiratory burst. The recombinant anti-RhD antibodies were specific for the RhD antigen and were able to mediate a respiratory burst. Thus these antibodies might be of use as future rhesus prophylaxis.
35 多年来,由 RhD 引起的胎儿及新生儿溶血病(HDFN)已通过从同种免疫的女性或经刻意免疫的男性获得的抗 RhD 抗体得到有效预防。然而,由于免疫女性数量减少以及伦理原因,预计将需要其他抗 RhD 来源。其中一种来源是重组人抗体。在此,我们描述了编码抗 RhD 抗体两个亚类(IgG1 和 IgG3)的质粒构建、它们在 COS 细胞中的瞬时表达,以及随后关于抗体特异性和介导呼吸爆发能力的功能表征。重组抗 RhD 抗体对 RhD 抗原具有特异性,并能够介导呼吸爆发。因此,这些抗体可能用作未来的恒河猴预防措施。